论文部分内容阅读
目的研究不同剂量缬沙坦对代谢综合征患者血压及胰岛素抵抗的影响,为临床治疗提供指导依据。方法将2012年1~12月在本科住院及门诊治疗的代谢综合征患者60例随机分为Ⅰ组(缬沙坦80 mg组)和Ⅱ组(缬沙坦160 mg组)各30例,两组患者治疗前后行动态血压监测、空腹血糖(FBG)、空腹胰岛素(FINS)及胰岛素抵抗指数(HOMA-IR)检查。结果①治疗后两组患者血压水平均较治疗前明显降低,缬沙坦160 mg组较80 mg组更为明显,差异有统计学意义(P<0.05)。②两组患者治疗后胰岛素抵抗指数均较前降低,但缬沙坦160 mg组下降幅度更大,差异有统计学意义(P<0.05)。结论缬沙坦对降低代谢综合征患者血压及改善其胰岛素抵抗疗效确切,并存在剂量相关性。
Objective To study the effects of valsartan on blood pressure and insulin resistance in patients with metabolic syndrome and provide guidelines for clinical treatment. Methods Sixty patients with metabolic syndrome undergoing hospitalization and outpatient treatment from January to December in 2012 were randomly divided into group Ⅰ (30 mg valsartan) and group Ⅱ (30 mg valsartan 160 mg) Before and after treatment, ambulatory blood pressure monitoring, fasting blood glucose (FBG), fasting insulin (FINS) and insulin resistance index (HOMA-IR) were performed in all patients. Results ① After treatment, the blood pressure of both groups was significantly lower than that before treatment, valsartan 160 mg group was more obvious than 80 mg group, the difference was statistically significant (P <0.05). ② After treatment, the insulin resistance index of both groups was lower than before, but the decrease of valsartan 160 mg group was more significant, the difference was statistically significant (P <0.05). Conclusion Valsartan is effective in lowering blood pressure and improving insulin resistance in patients with metabolic syndrome, and there is dose-dependent relationship.